急性白血病异基因造血干细胞移植后的维持治疗研究进展  

Research progress on maintenance therapy following allogeneic hematopoietic stem cell transplantation for acute leukemia

作　　者：杨楚婷 郑雅龄 吴明(综述)[1] 黄睿(审校)[1] Chuting Yang;Yaling Zheng;Ming Wu;Rui Huang(Department of Hematology,Zhujiang Hospital,Southern Medical University,Guangzhou 510282,China)

机构地区：[1]南方医科大学珠江医院血液内科,广州市510282

出　　处：《中国肿瘤临床》2024年第12期635-639,共5页Chinese Journal of Clinical Oncology

摘　　要：急性白血病(acute leukemia,AL)是来源于造血干细胞的恶性克隆性疾病,分为急性淋巴细胞白血病(acute lymphoblastic leukemia,ALL)和急性髓细胞白血病(acute myeloid leukemia,AML)两大类。异基因造血干细胞移植(allogeneic hematopoietic stem cell transplantation,allo-HSCT)是AL患者获得长期生存有力的手段,但移植后复发仍然是导致其死亡的主要原因。移植前状态、移植预处理、移植后复发防治均影响移植后的复发。目前,有部分患者移植后维持治疗的研究开展,包括表观遗传学药物、靶向药物、免疫药物等移植后维持治疗。本文主要讨论移植后维持治疗与预后的关系,综述近年来急性白血病allo-HSCT后维持治疗的方法、治疗结局和潜在的不良反应。Acute leukemia(AL)is a malignant clonal disease caused by hematopoietic stem cells.Depending on the cell type involved,AL is classified as acute lymphoblastic leukemia(ALL)or acute myeloid leukemia(AML).Allogeneic hematopoietic stem cell transplantation(allo-HSCT)is an important and effective treatment for patients with AL to achieve long-term survival.However,recurrence after transplantation remains the primary cause of death.Pretransplantation status,transplantation conditioning,and prevention of post-transplantation relapse affects post-transplantation outcomes.This review focuses on post-transplantation maintenance therapy.Several studies on post-transplantation maintenance therapy are discussed,including research on post-transplantation maintenance therapy with epigenetic drugs,targeted drugs,and immunologic drugs.

关 键 词：急性白血病 异基因造血干细胞移植 维持治疗 靶向治疗 免疫治疗 

分 类 号：R733.71[医药卫生—肿瘤] R457.7[医药卫生—临床医学]